Khanolkar and colleagues recently reported the outcomes of a phase II study investigating intensification of GvHD prophylaxis with ATG based on IL-2 levels on day + 7; the authors observed an effective reduction in GvHD rate, at the expense of higher infection-related mortality [44]. This evidence concerns the gene IL2 and graft versus host disease.